mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-3-91-96mrj-1054Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSПервые результаты 6-летнего динамического наблюдения пациента с ранним псориатическим артритом, леченного в рамках стратегии «Лечение до достижения цели»The first results of a 6-year follow-up study of a patient with early psoriatic arthritis treated with a treat-to-target strategyТремаскинаП. О.TremaskinaP. O.

Полина Олеговна Тремаскина

115522, Москва, Каширское шоссе, 34А

Polina Olegovna Tremaskina

34A, Kashirskoe Shosse, Moscow 115522

polinatrem@yandex.ruЛогиноваЕ. Ю.LoginovaE. Yu.

115522, Москва, Каширское шоссе, 34А

 34A, Kashirskoe Shosse, Moscow 115522

КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СухининаА. В.SukhininaA. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2020210920201439196Copyright © Тремаскина П.О., Логинова Е.Ю., Коротаева Т.В., Сухинина А.В., 20202020Тремаскина П.О., Логинова Е.Ю., Коротаева Т.В., Сухинина А.В.Tremaskina P.O., Loginova E.Y., Korotaeva T.V., Sukhinina A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1054

В статье приводится характеристика основных принципов стратегии «Лечение до достижения цели» («Treat to target», T2T) при спондилоартритах, включая псориатический артрит (ПсА). Данные наблюдательных когорт свидетельствуют о том, что отсутствие адекватной терапии ПсА увеличивается риск структурного прогрессирования. На основании результатов, полученных в международном рандомизированном контролируемом исследовании TICOPA, а также Российском открытом наблюдательном исследовании РЕМАРКА, обоснована необходимость использования стратегии Т2Т на ранней стадии ПсА. Проанализированы собственные результаты 6-летнего наблюдения за пациентом с ранним ПсА, при лечении которого была применена стратегия Т2Т.

The paper characterizes the basic principles of a treat-to-target (T2T) strategy for spondyloarthritis, including psoriatic arthritis (PsA). The data from observational cohort studies suggest that inadequate therapy for PsA increases the risk of structural progression. The results, obtained in the international randomized controlled Tight Control of Psoriatic Arthritis (TICOPA) trial and the Russian open-label observational REMARCA study, have justified the necessity of using the T2T strategy for early-stage PsA. The authors have analyzed their own results of a 6-year follow-up study of a patient with early PsA, in whom the T2T strategy was used.

спондилоартритыпсориатический артритранняя стадиястратегия «Лечение до достижения цели»spondyloarthritispsoriatic arthritisearly stagetreat-to-target strategyReferencesКоротаева ТВ. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2014;52(6):650-9. doi: 10.14412/1995-4484-2014-650-659Korotaeva TV. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):650-9. (In Russ.). doi: 10.14412/1995-4484-2014-650-659Насонов ЕЛ, Коротаева ТВ, Лила АМ, Кубанов АА. Можно ли предотвратить развитие псориатического артрита у пациентов с псориазом? Научно-практическая ревматология. 2019;57(3):250-4. doi: 10.14412/1995-4484-2019-250-254Nasonov EL, Korotaeva TV, Lila AM, Kubanov AA. Can the development of psoriatic arthritis be prevented in patients with psoriasis? Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(3):250-4. (In Russ.). doi: 10.14412/1995-4484-2019-250-254Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019 Mar; 15(3):153-66. doi: 10.1038/s41584-019-0175-0.Scher JU, Ogdie A, Merola JF, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019 Mar; 15(3):153-66. doi: 10.1038/s41584-019-0175-0.Van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a doubleblind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019 May;78(5):610-16. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.Van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a doubleblind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019 May;78(5):610-16. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.Guldberg-M ∅ ller J, Cordtz RL, Kristensen LE, et al. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. 2019 Nov; 78(11):1517-23. doi: 10.1136/annrheumdis2019-215313. Epub 2019 Jul 12.Guldberg-M ∅ ller J, Cordtz RL, Kristensen LE, et al. Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark. Ann Rheum Dis. 2019 Nov; 78(11):1517-23. doi: 10.1136/annrheumdis2019-215313. Epub 2019 Jul 12.Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. CJEM. 2017 Mar;19(2): 156-8. doi: 10.1017/cem.2015.105. Epub 2015 Nov 20.Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. CJEM. 2017 Mar;19(2): 156-8. doi: 10.1017/cem.2015.105. Epub 2015 Nov 20.Smolen JS, Schöls M, Braun J, et al Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.Smolen JS, Schöls M, Braun J, et al Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6.Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford). 2019 Dec 1; 58(12):2251-59. doi: 10.1093/rheumatology/kez215.Wervers K, Luime JJ, Tchetverikov I, et al. Comparison of disease activity measures in early psoriatic arthritis in usual care. Rheumatology (Oxford). 2019 Dec 1; 58(12):2251-59. doi: 10.1093/rheumatology/kez215.Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010 Jul;62(7):970-6. doi: 10.1002/acr.20162.Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010 Jul;62(7):970-6. doi: 10.1002/acr.20162.Коротаева ТВ, Логинова ЕЮ, Каратеев ДЕ и др. Стратегия «Лечение до достижения цели» при раннем псориатическом артрите (предварительные результаты исследования РЕМАРКА). Научно-практическая ревматология. 2014;52(4):376–80. doi: 10.14412/1995-4484-2014-376-380Korotaeva TV, Loginova EYu, Karateev DE, et al. Treat-to-target strategy for early psoriatic arthritis (preliminary results of the REMARCА study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):376–80. (In Russ.). doi: 10.14412/1995-4484-2014-376-380Логинова ЕЮ, Коротаева ТВ, Смирнов АВ и др. Особенности поражения осевого скелета при раннем псориатическом артрите (исследование РЕМАРКА). Научно-практическая ревматология. 2016; 54(Прил 1):15-9. doi: 10.14412/1995-4484-2016-1S-15-19Loginova EYu, Korotaeva TV, Smirnov AV, et al. Specific features of axial skeleton involvement in early psoriatic arthritis (the REMARCA trial). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(1S):15-9. (In Russ.). doi: 10.14412/1995-4484-2016-1S-15-19Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 16;21(1):25. doi: 10.1186/s13075-0191811-4.Wervers K, Luime JJ, Tchetverikov I, et al. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 16;21(1):25. doi: 10.1186/s13075-0191811-4.Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. Jan-Feb 2015;33(1):11-9. Epub 2014 Dec 22.Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin Exp Rheumatol. Jan-Feb 2015;33(1):11-9. Epub 2014 Dec 22.Strand V, Mease P, Gossec L, et al. FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203-7. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.Strand V, Mease P, Gossec L, et al. FUTURE 1 study group. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017 Jan;76(1):203-7. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis. 2016 Apr;75(4):640-3. doi: 10.1136/annrheumdis2015-208617. Epub 2015 Dec 15.Coates LC, Helliwell PS. Treating to target in psoriatic arthritis: how to implement in clinical practice. Ann Rheum Dis. 2016 Apr;75(4):640-3. doi: 10.1136/annrheumdis2015-208617. Epub 2015 Dec 15.

The authors declare that there are no conflicts of interest present.